Research programme: obesity therapy - Migenix

Drug Profile

Research programme: obesity therapy - Migenix

Alternative Names: MITO-3108; MX-3108

Latest Information Update: 06 Jun 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MIGENIX
  • Class
  • Mechanism of Action Methylmalonyl CoA mutase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Obesity

Most Recent Events

  • 30 Apr 2006 Discontinued - Preclinical for Obesity in USA (Parenteral)
  • 18 Apr 2006 This programme is still in active development
  • 25 May 2005 Preclinical trials in Obesity in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top